U.S. Oil and Gas Stock News

Pacira BioSciences (NASDAQ:PCRX) has had a rough three months with its share price down 8.6%. It seems that the market...

JM Group (JMG) has put fresh numbers on the table for FY 2025, with second half revenue of HK$122.0 million and basic EPS of HK$0.39, while the trailing twelve months show revenue of HK$269.4 million and EPS of HK$1.17 backed by net income of HK$18.7 million. The company has seen revenue move from HK$92.1 million and EPS of HK$0.12 in 2H 2024 to HK$147.3 million and EPS of HK$0.78 in 1H 2025, before landing at the latest half year figures. Over the past year, earnings growth of 165.4% has...

If you are wondering whether American Water Works Company is fairly priced or not, this article will walk you through what its current share price might be implying about value. The stock recently closed at US$123.69, with returns of a 0.5% decline over 7 days, a 5.1% decline over 30 days, a 5.1% decline year to date, a 1.4% gain over 1 year, an 11.2% decline over 3 years and a 14.9% decline over 5 years. Recent moves in the share price have kept investor attention on how a regulated water...

The Sprinklr, Inc. ( NYSE:CXM ) share price has fared very poorly over the last month, falling by a substantial 25...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

If you are wondering whether Gold.com at US$62.87 is still attractively priced after a strong run, this article will walk through what the current market price might be implying about its value. The stock has strong recent return figures, including 22.1% over 7 days, 46.8% over 30 days, 80.8% year to date, 124.8% over 1 year and 117.2% over 3 years, with a 5-year return of around 4x. Recent market attention on Gold.com has been driven by these return numbers and broader interest in the...

In early February 2026, Voyager Technologies secured its sixth patent for the Bishop Airlock’s electrical power and data-interface architecture, deepening protection around its modular space-station infrastructure, while also adding a new NASA Johnson Space Center IDIQ mission management contract worth up to US$24.50 million over four years and breaking ground on a 150,000 sq ft defense manufacturing complex in Pueblo, Colorado. Together with a new partnership with Max Space on expandable...

Old Second Bancorp (NasdaqGS:OSBC) has authorized a new share repurchase program of up to $43.9 million. The buyback authorization extends through 2026. The program adds another capital return tool alongside existing balance sheet and lending activities. Old Second Bancorp, the holding company for Old Second National Bank, operates as a regional banking provider focused on lending, deposits, and other financial services. For investors, a new repurchase authorization of this size can be an...

Recent performance snapshot Stoke Therapeutics (STOK) has drawn fresh attention after recent share price moves, with the stock showing a 1 day return of about a 1% decline, alongside modest gains over the past week. Investors are also weighing its roughly 10% return over the past month and about 24% over the past 3 months, compared with longer term figures and the company’s early stage biopharmaceutical profile. See our latest analysis for Stoke Therapeutics. Looking beyond the recent moves,...

Scorpio Tankers Inc. ( NYSE:STNG ) shares have had a really impressive month, gaining 27% after a shaky period...

The market seemed underwhelmed by the solid earnings posted by Embecta Corp. ( NASDAQ:EMBC ) recently. We have done...

If you are wondering whether KBR's current share price lines up with its underlying worth, you are not alone and this article is here to help you size up that question quickly. KBR closed at US$40.90, with returns of 4.1% decline over 7 days, 7.7% decline over 30 days, a 1.0% gain year to date, and a 22.2% decline over 1 year, while the 5 year return sits at 36.7% and the 3 year return at 18.4% decline. Recent coverage around KBR has focused on its position in the commercial services space...

Klaviyo (KVYO) has capped FY 2025 with Q4 revenue of US$350.2 million and basic EPS of US$0.02, while on a trailing twelve month basis the business generated US$1.2 billion of revenue and a net loss of US$31.8 million. The company has seen quarterly revenue move from US$270.2 million in Q4 FY 2024 to US$350.2 million in Q4 FY 2025, and basic EPS shift from a loss of US$0.10 to a small profit of US$0.02 over the same period. This sets up an earnings season story that hinges on how durable this...

If you are looking at First Merchants and wondering whether the current share price still represents good value, you are not alone. The stock last closed at US$42.05, with returns of 0.5% over the past 7 days, 11.7% over 30 days, 12.1% year to date and a 1% decline over the past year, which may signal changing expectations around its prospects and risk. This article was prompted by Simply Wall St's evergreen coverage of First Merchants, which periodically refreshes to keep valuation and...

MNTN (MNTN) has put a cleaner set of numbers on the table for FY 2025 so far, with Q3 revenue of US$70.0 million and basic EPS of US$0.09 off net income of US$6.4 million, against a trailing twelve month backdrop that still shows a loss of US$44.9 million on revenue of US$272.8 million and EPS of US$1.25. The company has seen quarterly revenue move from US$54.8 million in Q2 2024 to US$70.0 million in Q3 2025. EPS has swung across losses of US$0.69, US$1.41 and US$0.65 in early FY 2025 before...

Key Insights Boston Beer Company's estimated fair value is US$329 based on 2 Stage Free Cash Flow to Equity Boston Beer...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Liberty Energy Inc. ( NYSE:LBRT ) shares have continued their recent momentum with a 27% gain in the last month alone...

Edwards Lifesciences FY 2025 earnings snapshot Edwards Lifesciences (EW) has wrapped up FY 2025 with fourth quarter revenue of US$1,569.6 million and basic EPS of US$0.11, setting the tone for how investors assess the latest stretch of results. The company has seen revenue move from US$1,385.8 million in Q4 2024 to US$1,569.6 million in Q4 2025, while basic EPS over that same period went from US$0.59 to US$0.11. This puts the focus squarely on how efficiently those sales are translating into...

Quest Diagnostics (NYSE:DGX) has introduced a blood based minimal residual disease test for multiple myeloma that uses advanced flow cytometry. The company reports that the assay offers sensitivity comparable to next generation sequencing with a lower expected cost and less invasive sampling. FDA draft guidance recognizes minimal residual disease as an endpoint in multiple myeloma clinical trials, supporting broader use of MRD testing in research. For you as an investor, this development...

Grab Holdings (NasdaqGS:GRAB) reports its first full year of net profit. The company launches a $500 million share buyback program. Grab announces the acquisition of Stash Financial to expand into wealth services. Grab partners with Hesai Technology to distribute lidar products across Southeast Asia. Grab Holdings is moving through a major shift, pairing its first full year of net profit with several new capital and business moves. The share price sits at $4.23, with a 3 year return of...

Acadia Realty Trust (NYSE:AKR) announced internal executive promotions tied to the planned retirement of its long-tenured Chief Administrative Officer, Joseph Napolitano. Erica Pipitone has been promoted to Vice President of Financial Reporting as part of the updated leadership structure. Napolitano is set to retire after 31 years with the company, marking a significant shift in its senior administrative team. Acadia Realty Trust focuses on retail real estate, so leadership in finance and...

FDA orphan drug designation puts Immatics (NasdaqCM:IMTX) melanoma program in focus Immatics (NasdaqCM:IMTX) is back on investor radars after the FDA granted orphan drug designation to its melanoma treatment for HLA-A 02:01-positive patients with Stage II and higher disease. See our latest analysis for Immatics. The orphan drug news lands after a sharp shift in sentiment, with the 1-year total shareholder return of 102.17% and recent 7-day and 30-day share price returns of 9.74% and 11.90%...

Qiagen (NYSE:QGEN) has introduced sustainability-focused consumables and new automated sample preparation systems for clinical laboratories. The lineup features the newly launched QIAsprint Connect, with QIAsymphony Connect and QIAmini planned to broaden automation options across different lab sizes. The company is positioning these platforms to support greener lab workflows and greater process efficiency in clinical testing environments. Qiagen is putting more attention on automation and...